Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
AMGN Amgen Inc. daily Stock Chart
Amgen Inc.
IndexS&P 500 P/E19.54 EPS (ttm)8.37 Insider Own0.13% Shs Outstand754.33M Perf Week2.53%
Market Cap123.35B Forward P/E15.38 EPS next Y10.63 Insider Trans-1.16% Shs Float753.16M Perf Month1.03%
Income6.43B PEG1.89 EPS next Q2.30 Inst Own82.00% Short Float1.04% Perf Quarter5.43%
Sales21.46B P/S5.75 EPS this Y0.90% Inst Trans-0.21% Short Ratio1.98 Perf Half Y5.15%
Book/sh36.94 P/B4.43 EPS next Y5.45% ROA9.20% Target Price184.55 Perf Year1.27%
Cash/sh41.26 P/C3.96 EPS next 5Y10.32% ROE23.90% 52W Range129.43 - 180.06 Perf YTD4.72%
Dividend3.16 P/FCF19.23 EPS past 5Y8.20% ROI10.20% 52W High-9.18% Beta0.73
Dividend %1.93% Quick Ratio5.10 Sales past 5Y6.50% Gross Margin79.80% 52W Low26.33% ATR3.66
Employees17900 Current Ratio5.40 Sales Q/Q13.80% Oper. Margin36.80% RSI (14)64.98 Volatility1.41% 2.33%
OptionableYes Debt/Eq1.14 EPS Q/Q51.60% Profit Margin30.00% Rel Volume0.26 Prev Close163.95
ShortableYes LT Debt/Eq1.09 EarningsOct 28 AMC Payout35.20% Avg Volume3.94M Price163.52
Recom2.40 SMA202.91% SMA507.57% SMA2004.34% Volume1,052,400 Change-0.26%
Oct-29-15Reiterated UBS Buy $168 → $180
Sep-01-15Initiated Raymond James Mkt Perform
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Jul-31-15Reiterated Deutsche Bank Buy $192 → $195
Jul-31-15Reiterated Barclays Equal Weight $180 → $185
May-28-15Reiterated Deutsche Bank Buy $200 → $192
Apr-22-15Reiterated UBS Buy $175 → $185
Apr-22-15Reiterated RBC Capital Mkts Outperform $178 → $185
Oct-29-14Reiterated Argus Buy $140 → $185
Oct-28-14Reiterated RBC Capital Mkts Outperform $150 → $165
Sep-08-14Reiterated RBC Capital Mkts Outperform $138 → $150
Aug-04-14Reiterated Argus Buy $135 → $140
Jul-30-14Reiterated RBC Capital Mkts Outperform $125 → $138
Jul-18-14Reiterated Deutsche Bank Buy $144 → $149
Apr-23-14Reiterated Oppenheimer Perform $121 → $122
Mar-21-14Reiterated Barclays Equal Weight $115 → $130
Jan-31-14Reiterated Argus Buy $130 → $135
Nov-20-13Reiterated Deutsche Bank Buy $138 → $142
Aug-29-13Reiterated UBS Buy $121 → $124
Aug-27-13Reiterated Barclays Overweight $105 → $115
Nov-28-15 03:41PM  What Healthcare Dividend Stock Is Best? at Motley Fool
07:40AM  Amgen Inc. Takes Aim at AbbVie Inc. at Motley Fool
Nov-27-15 04:10PM  Amgen Seeks FDA Approval for First Biosimilar of Humira
09:30AM  The Zacks Analyst Blog Highlights: BioMarin, Amgen, Vertex, Gilead, Biogen and Repros
03:06AM  Novartiss Cosentyx: Europes First IL-17A Inhibitor for Some Uses
Nov-25-15 07:39PM  Biotech ETFs Beat The Gloom; Gold At Lows at Investor's Business Daily
05:19PM  Biotechs Weaken, But These Names Have Bullish Charts at Investor's Business Daily
04:27PM  Amgen applies to FDA for competitor drug to AbbVie's Humira at MarketWatch
04:11PM  Amgen files for U.S. approval of biosimilar to Humira Reuters
04:00PM  Amgen's First Biosimilar Biologics License Application For ABP 501 Submitted To U.S. Food And Drug Administration PR Newswire
03:57PM  Novartis: Clinical Trials Show Cosentyxs Superior Efficacy
10:15AM  Biotech Stock Roundup: KaloBios Soars as Shkreli Steps In, FDA Panel Not Convinced about BioMarin Drug
09:06AM  Short Sellers Run for Cover From Major Biotechs at 24/7 Wall St.
09:04AM  Johnson & Johnson's Latest FDA Approval Could Spell Problems for Amgen at Motley Fool
Nov-24-15 04:53PM  Amgen Gained as CVS Sealed the Deal to Sell Repatha
02:31PM  Hedge Fund Favorite: GILD
01:40PM  Amgen's Repatha Gets Preferred Position on CVS Formularies
08:38AM  Healthcare's Greatest Dividend Stocks at Motley Fool
02:00AM  European Commission Approves Amgen's BLINCYTO® (blinatumomab) for the Treatment of Adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia PR Newswire
Nov-23-15 04:49PM  Will Celgene Raise Its 2020 Outlook? at
04:06PM  CVS' Amgen Pick 'Raises The Bar' For Regeneron, Sanofi at Investor's Business Daily
01:22PM  Amgen (AMGN) Stock Rises on CVS Health Partnership at TheStreet
11:33AM  Uh Oh, CVS Prefers Amgen's Cholesterol Drug to Regeneron's at
08:10AM  CVS Chooses New Cholesterol Drug for Caremark at The Wall Street Journal
08:10AM  Amgen Announces Repatha® Preferred Position On CVS Health Commercial Formularies PR Newswire
08:00AM  CVS chooses Amgen's new cholesterol drug over competitor Reuters
08:00AM  CVS Makes Exclusive Deal to Cover Amgens Cholesterol Drug at Bloomberg
Nov-21-15 08:00AM  5 Things Amgen, Inc. Wants You to Know at Motley Fool
Nov-20-15 06:08PM  The Best Healthcare ETF of the Week at Motley Fool
05:44PM  Better Dividend Stock: Amgen or AstraZeneca PLC? at Motley Fool
04:40PM  Amgen's Multiple Myeloma Drug Kyprolis Gains EU Approval
03:53PM  How Has PBE Performed in the Market This Year?
02:51PM  Expedia plans layoffs, $150 million in severance payments related to Orbitz acquisition at
10:36AM  This May be Biotechs Next Huge Winner
10:07AM  The Market Response to the FDAs Approval of Darzalex
09:59AM  Biotech: Let It Bleed at
08:34AM  Health care is the best pick for 2016, despite Thursday's drop: Strategist
Nov-19-15 04:35PM  Novartis: FDA Accepts BLA for Biosimilar Version of Neulasta
02:30PM  Gilead Leads a Biotech Rally at TheStreet
01:15PM  Clinical Trials Demonstrated Darzalexs Efficacy Profile
01:14PM  FDA Approval of Johnson & Johnsons Darzalex for Multiple Myeloma
10:10AM  Stock Market News for November 19, 2015
10:02AM  Amgen's Repatha Is Too Bloody Pricey for the U.K. at Motley Fool
09:35AM  Billionaire Dan Loebs Top Picks For A Fourth Quarter Recovery at Insider Monkey
Nov-18-15 04:30PM  Ackman's Modest Allergan Proposal at Bloomberg
03:01PM  Amgen Rises by 2% as XBIs Large-Cap Stocks Rally
11:35AM  Sarepta Could Crush It, Even with a Broken FDA
11:16AM  Biotech: 'We Would Hold Off on Any New Purchases' at
09:23AM  Robin Hood Investment Conference
08:03AM  UK cost watchdog turns down Amgen's new cholesterol drug Reuters
06:11AM  The PowerShares Dynamic Pharmaceuticals ETF: Holdings Breakdown
02:17AM  Novartis biosimilar takes aim at Amgen drug Neulasta Reuters
01:36AM  FDA accepts Sandoz submission for biosimilar of Amgen's Neulasta Reuters
Nov-17-15 12:00PM  Amgen (AMGN) Stock is the 'Chart of the Day' at TheStreet
11:22AM  Five Jaw Dropping Visuals: GOOGL, MSFT, DIS, Biotech
09:42AM  3 Biotech Stocks You Don't Have to Babysit at Motley Fool
09:34AM  AstraZenecas Tagrisso Approved by FDA for Lung Cancer
Nov-16-15 04:00PM  Amgen to Present IMLYGIC (Talimogene Laherparepvec) Data at the 2015 International Congress of the Society for Melanoma Research PR Newswire
12:36PM  Billionaire Dan Loeb Grows Bearish on the Market As Short Positions Outpace His Conviction Buys at Insider Monkey
12:04PM  Amgens Bone and Nephrology Drugs Register Solid Growth in 3Q15
10:05AM  Five Mind Blowing Charts: AAPL, NFLX, AMZN, FB, GILD
Nov-14-15 07:21AM  These 2 Companies Could Revolutionize Heart Disease Prevention at Motley Fool
Nov-13-15 11:47PM  Need help paying for Amgen's Repatha? Get ready to give up your privacy at Los Angeles Times
02:16PM  Merck continuing study of cholesterol drug in new class
01:18PM  The Stock Leading the Genomics Revolution
12:02PM  A Bounty of Data Pushes Amgen Higher by 14% in October at Motley Fool
09:10AM  Kite Pharma (KITE) Posts Narrower Than Expected Loss in 3Q
12:05AM  Amgen Uses Its Expertise to Develop Biosimilars in 3Q15
Nov-12-15 01:46PM  3 Top Biotech Stocks See Their Short Interest Plunge
01:06PM  The PowerShares Dynamic Pharmaceuticals ETF: PJPs 2015 Performance
11:27AM  Regeneron Recovers From Clinton Biotech Beat Down at Investor's Business Daily
10:30AM  7 Cash-Rich Stocks to Add to Your Portfolio at Kiplinger
10:30AM  Regeneron In Buy Zone As Arthritis Drug Shows Promise
06:58AM  4 Observations You May Have Overlooked in Celgene's Q3 Earnings Report at Motley Fool
Nov-11-15 10:45AM  Alnylam, Medicines Co cholesterol drug effective for 6 months-study Reuters
07:45AM  Short Sellers Run for Cover From Major Biotechs at 24/7 Wall St.
Nov-10-15 02:58PM  Why Aegerion Pharmaceuticals Is Crashing Today at Motley Fool
02:05PM  Kite (KITE) to Report 3Q Earnings: What's in Store?
10:16AM  5 Breakout Stocks to Buy Now at TheStreet
09:07AM  Celgenes Revlimid Continues to Dominate Multiple Myeloma Market
08:30AM  Big Pharma's Shoes Don't Fit Amgen at Bloomberg
07:05AM  Buy Amgen's Healthy Dividend, Hold for Its Growth Prescription at TheStreet
Nov-09-15 05:30PM  Amgen Presents Detailed Results From Phase 3 Study Demonstrating Clinical Equivalence Of Biosimilar Candidate ABP 501 With Adalimumab PR Newswire
01:49PM  What Does 2016 Hold for This Closely-Watched Biotech ETF? at Motley Fool
09:31AM  Sivik Global Healthcares Top Biotech Stock Picks For Q4 at Insider Monkey
08:07AM  Myriad Genetics: Top Performer in the Biotechnology Subgroup
05:24AM  Amgen on the hunt for potential $10bn deal at Financial Times
Nov-08-15 03:45PM  Cytokinetics, Amgen drug shows promise in heart failure study
03:45PM  Amgen And Cytokinetics Announce Late-Breaking Presentation Of COSMIC-HF Trial At AHA Scientific Sessions 2015 PR Newswire
03:45PM  Amgen and Cytokinetics Announce Late-Breaking Presentation of COSMIC-HF Trial at AHA Scientific Sessions 2015 GlobeNewswire
Nov-07-15 04:43PM  ICYMI: Berkshire Hathaway Just Reported Earnings Of $2,769 Per Share
03:00PM  Amgen Presents Detailed Data Comparing Etelcalcetide With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis PR Newswire
01:05PM  Insulet Delivers Healthy Q3 Revenue Growth; Stock Pumps Up 14% at Motley Fool
Nov-06-15 05:07PM  Gilead and 2 Biotech Picks Value Investors Will Love
04:01PM  FDA Accepts Amgen's New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide PR Newswire
01:04PM  AMGEN INC Financials
11:22AM  Biotech Sees Better-than-Expected Earnings: ETFs in Focus
10:49AM  WATCH: Valeant Collapse Is Tumbling to Disaster (Video)
10:10AM  What Analysts Recommend for Gilead Sciences after 3Q15 Earnings
09:07AM  Why Amgens Valuation Multiples Remained Stable
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company's principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis. The company's other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has strategic collaboration with Xencor, Inc.; and collaborative agreements with AstraZeneca Plc, Takeda Pharmaceutical Company Limited, UCB, Novartis AG, and Bayer HealthCare Pharmaceuticals Inc. The company was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
de Carbonnel FrancoisDirectorAug 31Sale153.845,000769,19215,150Sep 02 07:46 PM
Hassan FredDirectorAug 19Buy166.633,010501,5623,582Aug 20 05:58 PM
PELHAM JUDITH CDirectorJul 31Sale180.405,035908,31411,890Aug 04 06:31 PM
Patton Cynthia MSVP & CCOJun 02Sale157.064,530711,48216,571Jun 03 07:16 PM
Balachandran MadhavanEVP, OperationsMay 07Option Exercise55.7221,7501,211,94855,144May 11 04:56 PM
Balachandran MadhavanEVP, OperationsMay 07Sale157.8721,7503,433,69533,394May 11 04:56 PM
Tross Stuart ASVP, Human ResourcesApr 23Sale169.313,012509,96421,923Apr 24 04:53 PM
Harper Sean EEVP, Research & DevelopmentApr 22Sale171.5828,0004,804,24047,920Apr 23 05:04 PM
Tross Stuart ASVP, Human ResourcesMar 03Sale157.744,415696,42720,237Mar 04 08:25 PM
BALTIMORE DAVIDDirectorMar 02Sale158.763,647579,01131,159Mar 03 08:55 PM
BALTIMORE DAVIDDirectorFeb 19Option Exercise42.135,000210,65036,159Feb 23 04:13 PM
Bradway Robert AChairman, CEO and PresidentFeb 11Option Exercise42.1384,0003,538,920258,641Feb 12 09:09 PM
Bradway Robert AChairman, CEO and PresidentFeb 11Sale152.6922,0003,359,116218,102Feb 12 09:09 PM
COFFMAN VANCE DDirectorFeb 06Option Exercise42.135,000210,65038,460Feb 06 06:23 PM
HERRINGER FRANK CDirectorFeb 05Option Exercise42.135,000210,65025,449Feb 05 08:11 PM
HERRINGER FRANK CDirectorFeb 05Buy152.293,000456,8702,000Feb 05 08:11 PM
de Carbonnel FrancoisDirectorDec 03Sale168.013,000504,04119,159Dec 03 05:00 PM